Vivaldi Biosciences Inc.
Vivaldi Biosciences Inc. Announces Issuance of US Patent for Influenza Vaccines
Published in TB and Outbreaks Week, October 20th, 2009
Vivaldi Biosciences Inc. (Vivaldi), a biotechnology company focused on development of vaccines for influenza, announced that the United States Patent and Trademark Office has issued US Patent 7,588,768 covering live attenuated influenza vaccines (LAIVs) with modifications to the viral NS1 gene, and methods for producing the vaccines in cell culture systems. This proprietary technology is applicable to rapid development and production of LAIVs against virtually all seasonal and pandemic influenza strains, including novel (swine-origin) H1N1. Vivaldi has exclusive rights to the patented technology and has LAIV candidates in development.
Live attenuated vaccines replicate...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Stanford University Medical Center
Stanford analyses of flu pandemics project savings from earlier vaccinations - University of Texas Health Science Center at Houston
New chemically activated antigen could expedite development of HIV vaccine - Bird Flu
Research from Zhejiang University provides new data about bird flu - Bird Flu
Scientists at Alabama State University detail research in bird flu - Central Nervous System Infection
Reports outline central nervous system infection study results from J. Dassarma et al - Clinical Infectious Diseases
New clinical infectious diseases study findings reported from Chang Gung Memorial Hospital - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
